Immuneering Corp (IMRX) Live Share Price, Invest From India

Immuneering Corp Stock Performance

as on January 31, 2026 at 2:29 am IST

Day's Low
Day's High
$4.62
Day's Price Range
$4.98
$4.63
0.22%
Downside
7.56%
Upside
52 Week's Low
52 Week's High
$1.10
52-Week Price Range
$10.08
$4.63
76.24%
Downside
117.71%
Upside

Immuneering Corp share price movements today

Previous Close: $4.87
Open: $4.83
Volume: 926.3K
Day's Low - High: $4.62 - $4.98
52 Week Low - High: $1.10 - $10.08

Immuneering Corp Historical Returns

1 Month Return: -29.64 %
3 Month Return: -32.61 %
1 Year Return: + 138.66 %
3 Year Return: + 10.5 %
5 Year Return: 0 %

Immuneering Corp Stock Fundamentals & Key Indicators

Check Immuneering Corp market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$337.1M

EPS (TTM)

-1.4167

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-0.67

Industry PE ratio

PEG Ratio

EBITDA

-63.8M

Revenue (TTM)

455.0

Profit Margin

0.00%

Return On Equity TTM

-43.75%

Immuneering Corp Stock Valuation

Track how Immuneering Corp P/E has moved over time to understand its valuation trends.

Immuneering Corp in the last 5 years

Overview
Trends

Lowest (-6.47x)

December 31, 2021

Industry (0.00x)

January 31, 2026

Today (-0.67x)

January 31, 2026

Highest (-0.61x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: -0.67x

Immuneering Corp vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immuneering Corp with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Immuneering Corp	BUY	$337.1M	NA	-0.67	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$47.7B	124.65%	1246.03	1.36%
Vertex Pharmaceuticals Incorporated	BUY	$122.3B	105.12%	33.56	31.35%
Beone Medicines Ltd	NA	$37.4B	NA	662.33	1.38%
Regeneron Pharmaceuticals, Inc.	BUY	$80.8B	47.16%	18.28	32.13%

Stock Returns calculator for Immuneering Corp Stock including INR - Dollar returns

The Immuneering Corp stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Immuneering Corp investment value today

Current value as on today

₹2,44,528

Returns

₹1,44,528

(+144.53%)

Returns from Immuneering Corp Stock

₹1,38,660 (+138.66%)

Dollar Returns*

₹5,869 (+5.87%)

Analyst Recommendation on Immuneering Corp Stock

Based on 14 analysts

BUY

71.43%

Buy

28.57%

Hold

0.00%

Sell

Based on 14 analysts, 71.43% of analysts recommend a 'BUY' rating for Immuneering Corp. Average target price of $16.83

Immuneering Corp Share Price Target

Get share price movements and forecasts by analysts on Immuneering Corp.

What analysts predicted

72.49%UPSIDE

Target Price

$16.83

Current Price

$4.63

Analyzed by

14 Analysts

Target

$16.83

Immuneering Corp target price $16.83, a slight upside of 72.49% compared to current price of $4.63. According to 14 analysts rating.

Immuneering Corp Stock’s Investor Sentiment and Interest

Search interest for Immuneering Corp Stock has increased by 249% in the last 30 days, reflecting an upward trend in search activity.

Time period: January 1, 2026 to January 31, 2026

Change:249% versus previous 30 day period

Immuneering Corp Quarterly Profit & Loss

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Total Revenue	94	-	-94	-	-	-	0	-	-	-
Gross Profit	0	0	0	0	0	0	0	0	0	0
Operating Income	-13	-13	-16	-15	-14	-15	-18	-15	-14	-15
EBITDA	-11	-13	-14	-15	-14	-15	-17	-15	-14	-14
Interest Expense	-	-	1,075	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-12	-12	-15	-14	-14	-14	-18	-15	-14	-14
Income Tax Expense	-1	-13,912	0	0	0	0	0	-	-	-
Net Income	-12	-12	-15	-14	-14	-14	-18	-15	-14	-14
Net Profit Margin	-12.91%	0.00%	15.98%	0.00%	0.00%	0.00%	-2485.31%	0.00%	0.00%	0.00%

Immuneering Corp Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	1	2	2	0	0	-
Gross Profit	0	1	0	0	0	0
Operating Income	-6	-17	-33	-51	-58	-64
EBITDA	-7	-17	-33	-51	-58	-63
Interest Expense	0	0	0	1	-	-
Depreciation	0	0	0	0	0	0
Income Before Tax	-7	-17	-33	-50	-53	-61
Income Tax Expense	0	0	0	-1	0	-
Net Income	-7	-17	-33	-50	-53	-61
Net Profit Margin	-401.59%	-737.17%	-1612.33%	-15937.29%	-11752004.84%	0.00%

Immuneering Corp Quarterly Cash Flow

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Net Income	-12	-15	-14	-14	-14	-18	-15	-14	-14
Operating Cash Flow	-12	-11	-15	-11	-13	-14	-14	-9	-11
Investing Cash Flow	-23	3	21	4	-5	5	0	0	0
Financing Cash Flow	0	0	0	-	4	0	13	0	213
Change in Cash	-35	-8	6	-6	-14	-9	0	-9	201

Immuneering Corp Annual Cash Flow

All numbers in Millions USD

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-17	-33	-50	-53	-61
Operating Cash Flow	-14	-30	-44	-48	-54
Investing Cash Flow	0	-75	41	7	26
Financing Cash Flow	37	144	0	28	5
Change in Cash	23	37	-2	-13	-23

Global Institutional Holdings in Immuneering Corp

Funds	Holdings
Geode Capital Management, LLC	0.54%
FMR Inc	0.52%
CI Private Wealth LLC	0.15%
Northern Trust Corp	0.09%
Flower City Capital	0.08%

See all

Immuneering Corp News & Key Events

Insights on Immuneering Corp

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Best in 1 Year
In the last 1 year, IMRX has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, -94.41M → 726.32K (in $), with an average increase of 13099.5% per quarter
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 33.0% return, outperforming this stock by 22.5%
NEGATIVE IMPACT
Price Dip
In the last 7 days, IMRX stock has moved down by -13.6%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -14.43M → -14.96M (in $), with an average decrease of 3.7% per quarter

About Immuneering Corp

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Organisation	Immuneering Corp
Headquarters	245 Main Street, Cambridge, MA, United States, 02142
CEO	Dr. Benjamin J. Zeskind M.B.A., Ph.D.
E-voting on shares	Click here to vote

Key Management of Immuneering Corp

Name	Title
Mr. Robert J. Carpenter M.B.A., M.S.	Co-Founder & Chair Emeritus
Dr. Brett M. Hall Ph.D.	Chief Scientific Officer
Mr. Harold E. Brakewood	Chief Business Officer
Dr. Benjamin J. Zeskind M.B.A., Ph.D.	Co-Founder, President, CEO & Director
Mr. Michael D. Bookman J.D.	Chief Legal Officer & Secretary
Ms. Mallory Morales CPA	Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer
Ms. Paula George CPA	Director of Accounting & Operations and Assistant Corporate Controller
Ms. Leah R. Neufeld	Chief People Officer
Dr. Peter King Ph.D.	Head of Discovery & VP
Dr. Praveen Nair Ph.D.	Head of Translational Pharmacology & VP

FAQs

What is Immuneering Corp share price today?

Immuneering Corp share price today is $4.63 as on January 31, 2026 at 2:29 am IST at the close of the market. Immuneering Corp share today touched a day high of $4.98 and a low of $4.62.

What is the 52 week high and 52 week low for Immuneering Corp share?

Immuneering Corp share touched a 52 week high of $10.08 on September 22, 2025 and a 52 week low of $1.1 on May 12, 2025. Immuneering Corp stock price today i.e. January 31, 2026 at 2:29 am IST is closed at $4.63,which is 54.07% down from its 52 week high and 320.91% up from its 52 week low.

What is Immuneering Corp's market capitalisation today?

Immuneering Corp market capitalisation is $0.00T as on January 31, 2026 at 2:29 am IST.

How to invest in Immuneering Corp Stock (IMRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Immuneering Corp on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immuneering Corp Shares that will get you 0.3240 shares as per Immuneering Corp share price of $4.63 per share as on January 31, 2026 at 2:29 am IST.

What is the minimum amount required to buy Immuneering Corp Stock (IMRX) from India?

Indian investors can start investing in Immuneering Corp (IMRX) shares with as little as ₹91.641 or $1 (as of January 31, 2026 at 8:52 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹916.41 in Immuneering Corp stock (as per the Rupee-Dollar exchange rate as on January 31, 2026 at 8:52 pm IST). Based on Immuneering Corp share’s latest price of $4.63 as on January 31, 2026 at 2:29 am IST, you will get 2.1598 shares of Immuneering Corp. Learn more about fractional shares .